Literature DB >> 8540738

Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis.

C Cabellos1, J Martinez-Lacasa, A Martos, F Tubau, A Fernández, P F Viladrich, F Gudiol.   

Abstract

Using a rabbit model of meningitis, we sought to determine whether concomitant use of dexamethasone affects the penetration and efficacy of ceftriaxone or vancomycin in cerebrospinal fluid. Rabbits were inoculated with a penicillin-sensitive strain of Streptococcus pneumoniae and treated with ceftriaxone or vancomycin with or without dexamethasone. In the ceftriaxone-treated groups, no statistically significant differences were seen between the group treated with dexamethasone and that without dexamethasone; however, in the vancomycin-treated groups we found statistically significant lower cerebrospinal fluid vancomycin levels at 2 h in the dexamethasone-treated rabbits and differences in bacterial killing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8540738      PMCID: PMC162903          DOI: 10.1128/AAC.39.9.2158

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Dexamethasone in bacterial meningitis: increasing evidence for a beneficial effect.

Authors:  M G Täuber; M A Sande
Journal:  Pediatr Infect Dis J       Date:  1989-12       Impact factor: 2.129

2.  A single daily dose of ceftriaxone for bacterial meningitis in adults: experience with 84 patients and review of the literature.

Authors:  C Cabellos; P F Viladrich; R Verdaguer; R Pallares; J Liñares; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

3.  Association between persistence of pneumococcal meningitis and dexamethasone administration.

Authors:  M T Brady; S L Kaplan; L H Taber
Journal:  J Pediatr       Date:  1981-12       Impact factor: 4.406

4.  Fluorescence polarization immunoassay. iii. an automated system for therapeutic drug determination.

Authors:  M E Jolley; S D Stroupe; K S Schwenzer; C J Wang; M Lu-Steffes; H D Hill; S R Popelka; J T Holen; D M Kelso
Journal:  Clin Chem       Date:  1981-09       Impact factor: 8.327

5.  Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials.

Authors:  M H Lebel; B J Freij; G A Syrogiannopoulos; D F Chrane; M J Hoyt; S M Stewart; B D Kennard; K D Olsen; G H McCracken
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

6.  The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis.

Authors:  C M Odio; I Faingezicht; M Paris; M Nassar; A Baltodano; J Rogers; X Sáez-Llorens; K D Olsen; G H McCracken
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

7.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

8.  Effect of methylprednisolone on entry of ampicillin and gentamicin into cerebrospinal fluid in experimental pneumococcal and Escherichia coli meningitis.

Authors:  W M Scheld; J P Brodeur
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

Authors:  P F Viladrich; F Gudiol; J Liñares; R Pallarés; I Sabaté; G Rufí; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

10.  Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group.

Authors:  U B Schaad; U Lips; H E Gnehm; A Blumberg; I Heinzer; J Wedgwood
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

View more
  24 in total

Review 1.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Cerebrospinal fluid penetration of vancomycin in adults receiving adjunctive dexamethasone.

Authors:  Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2007-07       Impact factor: 3.725

3.  Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high-dosage cefotaxime.

Authors:  I R Friedland; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Authors:  R Nau; M Kinzig-Schippers; F Sörgel; S Schinschke; R Rössing; C Müller; H Kolenda; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults.

Authors:  Karen Ng; Vincent H Mabasa; Ivy Chow; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

6.  Gemifloxacin is effective in experimental pneumococcal meningitis.

Authors:  A Smirnov; A Wellmer; J Gerber; K Maier; S Henne; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 7.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

8.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

9.  Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy.

Authors:  R Nau; C Lassek; M Kinzig-Schippers; A Thiel; H W Prange; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Daptomycin in experimental murine pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Mark S Rouse; Cheol-In Kang; Diederik van de Beek; James M Steckelberg; Robin Patel
Journal:  BMC Infect Dis       Date:  2009-04-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.